



ADB – JAPAN FUNDS WEEK

27 JUNE – 1 JULY 2022

TOWARDS A PROSPEROUS AND
RESILIENT ASIA AND THE PACIFIC



From
the People of Japan

JFPR COVID-19 Response

**Session 1: Japan Fund for Prosperous and Resilient
Asia and the Pacific (JFPR) Anniversary Event**

 **ADB-JAPAN FUNDS WEEK**
27 JUNE – 1 JULY 2022
TOWARDS A PROSPEROUS AND RESILIENT ASIA AND THE PACIFIC



JFPR
Japan Fund for Prosperous and
Resilient Asia and the Pacific




From
the People of Japan

Presentation Outline


1. ADB's response to the pandemic: APVAX and technical assistance
2. JFPR COVID-19 window – summary of projects and importance of funding
3. Japanese expertise in regulation
4. Opportunities for JFPR: from COVID to UHC and vaccine manufacturing

1.1 ADB's response: Asia Pacific Vaccine Access Facility (APVAX)


- **\$9B facility to support fast, high quality, safe and equitable vaccine access by DMCs:** vaccine procurement + system strengthening
- 14 approved projects (17 DMCs covering all 5 regions)
- \$4.62B in ADB commitments (total with co-financing of \$6.4B)



of \$ 9B APVAX resources approved as **ADB financing**



of total project financing is for **vaccine PROCUREMENT**




Cumulative project vaccine **TARGET**

Vaccine doses **SECURED**

Vaccine doses **DELIVERED**

1.2 ADB's response: TA for capacity building to support APVAX



2.1 JFPR support for pandemic responses

JFPR COVID-19 Window

Directly builds capacity and infrastructure to address infectious diseases, mitigates impacts, supports safe recovery

- Committed 10 projects - 6 Projects/grants and 4 Technical Assistance projects (\$34M)
- Finalising 2 projects to be approved in 2022 - 1 Project Grants and 1 Technical Assistance (\$6M)

2.2 Importance of JFPR COVID Window


* Limited uptake of financing to build health systems through APVAX



Joining up community-level and health system responses

REGIONAL TA – lessons from civil society led initiatives during the pandemic and sharing innovations and best practices with health authorities

JFPR provides critical technical assistance that augments the impact of APVAX



Strengthening cross-sectoral connections for pandemic response and economic recovery

FIJI – airport, transport sector and health links strengthened for improved disease prevention and detection at points of entry

Focused funding but sufficiently flexible to meet changing needs during a pandemic



Addressing acute gaps in health systems that have value for long term health service delivery

SRI LANKA – equipping and modernizing the ambulance service and providing infection prevention and control training to frontline health staff

2.3 JFPR COVID Window projects

Economic recovery

Health system strengthening

Community-level responses

Operational support for vaccine delivery – oxygen, waste management, cold chain, private sector engagement (**IND** - \$5M; Jun 2021)

Improved testing, vaccine delivery, post-immunization surveillance (**MON** - \$5M; Jun 21)

Pre-hospital services – ambulances, facilities, personnel, protocols (**SRI**- \$3M; Aug 2021)

Disease surveillance, preparedness, outbreak response, (**CAM** - \$5M; Oct 2021)

Disease surveillance, preparedness, health information systems, mental health services for staff (**CAM** - \$5M; Oct 2021)

Outbreak response, health delivery (**MYA** - \$2M)

Disease prevention, social protection for vulnerable/livelihoods impacted by COVID-19 (**REGIONAL** - \$2M; Nov 2020)

Airport improvements, health system infrastructure, waste management (**COO** - \$2M; Oct 2021)

Airport infrastructure, improved testing, communications (**FIJ** - \$3M; May 2022)

Strengthening Multisectoral Technical Capacity to Respond to COVID-19 in Asia and the Pacific through the Travel and Tourism Sectors (**REGIONAL** - \$2M)

WASH+H – communications, community engagement, policy and practice (**REGIONAL** - \$2M; Nov 2020)

WASH+H – facilities, behavior change, emergency preparedness (**NEP** - \$5M; Jun 2021)

Final approvals pending

3. Japanese expertise in regulation

Expert regulatory advice

Single dose to multi-dose vials – advice from several RVAG members

Effective technology transfer to DMCs - criteria for success

ADB temporary waiver for facilities without WHO/SRA approval producing approved COVID-19 vaccines

Access to the latest scientific data

Information on vaccines financed by ADB or being considered for financing (Sinopharm, Sinovac, Covaxin)

Horizon scanning + monthly updates on new COVID-19 vaccines and therapeutics

Information sharing

COVID-19 vaccine implementation experiences DMCs related to pharmacovigilance

Regional Vaccine Advisory Group (RVAG)

12 national regulators including Japan's PMDA

+ ADB and WHO-WPRO

Expert advice from Dr Yasuhiro Fujiwara

4.1 Opportunities for JFPR: from COVID to UHC



RESPONSE

Sustain a flexible pandemic response

Ongoing procurement of **next generation vaccines, diagnostics and therapeutics**



RESILIENCE

Build resilient health systems

Establish **national Centers for Disease Control** to prevent, detect and respond to disease outbreaks and emerging health threats

Invest in **primary care, laboratory and surveillance systems** that strengthen the region's ability to anticipate and manage infectious disease outbreaks



PREPAREDNESS

Strengthen pandemic preparedness

Support **sustainable pharmaceutical manufacturing** focusing on financing, workforce, technology transfer, and regulation

Build **regulatory and clinical trial capacities** required to support the development, monitoring and approval of new health products

- Opportunity to prioritize longer-term health strengthening
- Ensure pandemic responses address identified needs and contribute to UHC
- Ensure UHC considers core public health capacities for health emergencies

5.2 Opportunities to strengthen regional vaccine security

Defining how to support vaccine manufacturing

Synthesizing what we know

Analysis of scale-up of manufacturing in India and People's Republic of China

Partnering with technical agencies for scale-up of manufacturing

Financing for vaccine manufacturing

Sovereign

DMCs are interested in new facilities e.g., Bangladesh, Indonesia

Nonsovereign

Projects for vaccine manufacturing and tech transfer to the region

Building people's knowledge and skills

Developing vaccine manufacturing skills in DMCs

Intensive 8-week course - Yonsei Uni, ROK

Improving understanding of what it takes to be a vaccine manufacturer

Short courses for senior policy makers/financiers

Capacity building for national regulatory authorities (NRAs)

Provision of support to NRAs to undertake the WHO-Listed Authority (WLA) process

Training health staff to implement COVID-19 vaccination plans

Community mobilisation, risk communication, data for decision making

- Vaccine security in Asia-Pacific was a missing element in the early pandemic response
- Improving vaccine security encompasses more than just building new facilities